(Corrects typographical error in headline)
Nov 18 (Reuters) – British cancer drug developer Ellipses Pharma on Wednesday said it was exploring a London listing through a deal with special purpose acquisition company Wolfram Resources.
• Established in 2017, Ellipses Pharma’s pipeline includes trials for drugs to treat non-small cell lung cancer and breast cancer
• The company plans to list its shares on the London bourse following a reverse takeover by shell company Wolfram Resources, whose terms are yet to be agreed
• The floatation will provide a much-needed boost to the UK’s market which has seen an exodus from companies eyeing higher valuations in markets like the United States
• Ellipses Pharma said it is targeting completing the transaction by early 2027
• The firm also expects an equity fundraise in conjunction with the deal
• Listing through a reverse takeover process will enable the company to raise additional capital from public company investors, founder and chair Chris Evans said
(Reporting by Simone Lobo in Bengaluru; Editing by Nivedita Bhattacharjee)

